Bufexamac

Research use only, not for human use.

Bufexamac is a COX inhibitor for IFN-α release.

Bufexamac is a COX inhibitor for IFN-α release.

Cell Viability Assay Cell Line:BE(2)-C cells Concentration:30 μM Incubation Time:6 days Result:Enhanced cell death of tumor cells.Cell Migration Assay Cell Line:mouse neutrophils Concentration:50-100 μM Incubation Time:30 min Result:Reduced fMLP (5μM) induced neutrophil migration.Western Blot Analysis Cell Line:Hela cells (ATCC: CCL-2)Concentration:1 mM Incubation Time:4-16 hResult:Induced HIF1-α protein and increased HIF1-α levels.ImmunofluorescenceCell Line:Hela cells (ATCC: CCL-2)Concentration:50-250 μM Incubation Time:4 h Result:Stabilized HIF1-α and accumulated in the nucleus.

Animal Model:Six-to-eight weeks old female C57BL/6 miceDosage:50-100 mg/kg Administration:Oral gavage (p.o.), seven days Result:Ameliorated the infiltration of lung inflammatory cells and injury to the lung in a dose-dependent manner.Relieved LPS-induced lung injury.Reduced LTB4 level and MPO activity.Reduced cytokine mRNA expressions in lung tissue and cytokine levels in BALF in LPS-induced ALI in mice.Animal Model:horses aged 2 to 7 years old and weighing 302 to 522 kg Dosage:20-100 mg Administration:Intraarticular (IA) injection, weekly, 6 times Result:Didn't effect on general health, hematological or serum biochemical variables, or organs.

Bufexamac | CP-1044-J-3 | CP 1044 J 3 | CP1044J3 | Droxaryl | Parfenac

Chromatin/Epigenetic

COX

IFN-α

Inflammation/Immunology

——

2438-72-4

223.27

C12H17NO3

>98% (HPLC)

Ethanol: 3 mg/mL (13.43 mM); DMSO: 45 mg/mL (201.54 mM)

O=C(NO)CC1=CC=C(OCCCC)C=C1

2-(4-butoxyphenyl)-N-hydroxyacetamide

(-20℃)

With Ice Pack

≥ 2 years